Scope
ASH addresses reinduction and consolidation for relapsed or refractory acute lymphoblastic leukaemia in adolescents and young adults. B-cell and T-cell disease require distinct decisions; central nervous system relapse and remission after CAR T-cell therapy have separate recommendations. The guidance combines disease-directed treatment with assessment of transplant suitability, residual disease and the developmental and psychosocial needs of this population. This summary uses the final published guideline, including qualifying remarks.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
B-cell disease: reinduction and treatment choice
- For relapsed or refractory B-ALL in adolescents and young adults, ASH strongly recommends blinatumomab over chemotherapy, with low-certainty evidence. High blast counts at relapse may require debulking before blinatumomab. [1]
- ASH also strongly recommends inotuzumab over chemotherapy for this population, with low-certainty evidence. Consider veno-occlusive disease risk if allogeneic transplantation is planned after inotuzumab. [1]
- The guideline does not rank blinatumomab, inotuzumab and CAR T-cell therapy against one another or establish their best sequence. Choose according to the individual, disease burden and eligibility for later consolidation, including transplantation. [1]
- Limited comparative data also prevent a recommendation choosing CAR T-cell therapy over chemotherapy or other immune-based therapies. This evidence gap coexists with recognized activity after relapse in single-arm studies. [1]
Consolidation and transplantation
- After a second or later remission induced by tisagenlecleucel or brexucabtagene autoleucel in transplant-naïve young people with relapsed B-ALL, ASH conditionally suggests allogeneic transplantation. Individual assessment and shared decisions remain essential because some may do well with CAR T-cell therapy alone and transplant risks may exceed benefit. [1]
- For relapsed B-ALL reaching a second or later remission, ASH conditionally favours allogeneic transplantation over chemotherapy alone as definitive consolidation. Evaluate performance status, organ function and comorbidities before proceeding. [1]
- The panel advises transplantation when primary refractory disease achieves remission. Some younger patients in second remission with lower-risk disease—late relapse and low residual disease after reinduction—may instead be considered for chemotherapy and/or immunotherapy alone. [1]
- For relapsed/refractory ALL proceeding to allogeneic transplantation, ASH conditionally suggests myeloablative conditioning containing total-body irradiation over chemotherapy-only conditioning. [1]
Isolated central nervous system relapse
- For isolated CNS relapse, give intrathecal chemotherapy in the context of systemic therapy. ASH strongly recommends this approach and strongly recommends against CNS radiation alone without systemic and intrathecal chemotherapy. [1]
- Evidence is insufficient to determine the added benefit of radiation alongside other CNS-directed treatment, or to recommend CAR T-cell therapy specifically for isolated CNS relapse. [1]
T-cell disease and research options
- For relapsed/refractory T-ALL, ASH conditionally suggests a nelarabine-based regimen. Previous frontline nelarabine exposure does not, on the available evidence, by itself preclude using it again. [1]
- Novel therapies for relapsed/refractory T-ALL, including CAR T-cell therapy, carry a research-only recommendation: offer participation in clinical trials when available and feasible. This is not a routine-treatment recommendation for these novel approaches. [1]
Assess response and provide comprehensive AYA care
- Measure response using minimal residual disease as standard care, for prognosis and sometimes treatment-intensity decisions. The detailed approach is cross-referenced to the separate frontline guideline. [1]
- Assess developmental needs, preferences and treatment goals. Provide flexible delivery when appropriate and access to teams experienced in adolescent and young-adult ALL where feasible. [1]
- Screen routinely for depression, anxiety and other psychological problems, and provide multidisciplinary psychosocial support. Assess social support and help patients access supportive communities, financial counselling and practical resources. [1]
- Discuss sexual health, orientation, preferences and gender identity from diagnosis through treatment and survivorship. Offer comprehensive fertility consultation before treatment when possible, with continuing multidisciplinary involvement. [1]
- Offer an appropriate clinical trial, introduce palliative care early and retain it throughout the course of care regardless of disease status. [1]
- Discuss goals of care before crises arise and revisit them at transitions such as relapse. Adapt discussions to developmental and cognitive level, centre the young person’s wishes and involve family or carers to the extent they want. [1]
Limitations and use
- These recommendations concern adolescents and young adults with relapsed/refractory disease, not a frontline regimen for all ages. Drug doses, schedules and complete transplant procedures are not provided in this summary.
- The transplant and nelarabine suggestions are conditional and based on very-low-certainty evidence. The strong CNS recommendations also have very-low-certainty evidence; strength is not a claim of high certainty.
- Absence of a comparative recommendation is not evidence that a therapy is ineffective. Research-only T-ALL interventions must not be presented as routine care.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Acute lymphoblastic leukaemia in adolescents and young adults: relapsed or refractory disease
Guideline recommendation text consulted
Publication details
- Issuing organisation
- ASH
- Resource type
- Clinical practice guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.